zh-twzhen
zh-twzhen

Oneness Biotech Co., Ltd., has been granted the Brazil Good Manufacturing Practice (B-GMP) certification for Bonvadis from Brazil ANVISA.

2022

Date

Title

2022-02-22

Oneness Biotech Co., Ltd. receives a Korean patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2022-02-21

The data of SNS812, an anti-Pan-COVID19 siRNA, co-developed by Oneness & MBS and supervised by NTU professors, were published today by EMBO Mol. Medicine.

>
2022-02-15

Oneness Biotech Co., Ltd. receives a Korean patent on the producing recombinant glycoproteins with modified glycosylation.

>
2022-02-14

Oneness Biotech has been invited to present at the “QIC Healthcare Forum” online investor’s conference organized by Quantum International Corporation.

>
2022-02-14

Oneness Biotech Co., Ltd. receives an Indian patent on the producing recombinant glycoproteins with modified glycosylation.

>
2022-01-25

Oneness Biotech Co., Ltd. receives a Korean patent on FB704A, an anti-IL6 fully-human antibody new drug.

>
2022-01-20

Oneness Biotech Co., Ltd. receives a European patent on the producing recombinant glycoproteins with modified glycosylation.

>
2022-01-19

Oneness Biotech Co., Ltd. receives a Canadian patent on FB704A, an anti-IL6 fully-human antibody new drug.

>
2022-01-11

A Hongkong patent titled “USE OF FLAVONOID COMPOUND IN PREPARATION OF COMPOSITION FOR HEALING WOUND” has been granted.

>
2022-01-04

Oneness Biotech to Present at the 40th Annual J.P. Morgan Healthcare Conference

>
2022-01-03

Clarification on the media report with regards to the donation by Oneness founder

>